Is It Time To Reconsider Chemed (CHE) After The Past Year’s 25% Share Price Slide?

• Wondering whether Chemed at around US$421 per share is offering good value or extra risk? This article walks through the key signals that can help you judge the stock for yourself.
• The share price has slipped about 1.1% over the last week, after a 9.2% gain over the past month. It is still down 0.6% year to date and 25.6% over the last year, which may have some investors reassessing both the upside and the risks.
• Recent coverage has focused on Chemed's position as a healthcare services stock at a time when many investors are rethinking their exposure to the sector, with attention on how companies balance growth investments and capital returns to shareholders. That backdrop helps frame the recent price swings, as the market weighs how Chemed’s business profile fits into changing risk and return preferences.
• Right now, Chemed scores a 5 out of 6 on Simply Wall St's valuation checks, which you can review in detail through its valuation score. The rest of this article will unpack how different valuation methods line up for the stock, while also pointing to a smarter way to interpret those results at the end.

Find out why Chemed's -25.6% return over the last year is lagging behind its peers.

Approach 1: Chemed Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Chemed is expected to generate in the future and discounts those amounts back to today, giving a single estimate of what the stock could be worth right now.

For Chemed, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is $385.0 million, and Simply Wall St has explicit free cash flow estimates out to 2027, with a projected $346.3 million in 2027. Beyond that, cash flows from 2028 to 2035 are extrapolated, with values ranging from about $354.9 million to $443.0 million based on the provided projection path.

When all these projected cash flows are discounted back to today using the DCF model, the estimated intrinsic value comes out at $688.49 per share. Compared with a current share price around $421, this implies the stock trades at about a 38.8% discount, which indicates the stock may be undervalued if the cash flow assumptions hold.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Chemed is undervalued by 38.8%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Chemed.

Approach 2: Chemed Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. This makes it a common starting point when you want to sanity check a stock’s pricing.

Higher growth expectations or lower perceived risk usually support a higher P/E ratio, while slower growth or higher risk tend to justify a lower multiple. Context therefore really matters when you compare numbers.

Chemed currently trades on a P/E of 21.44x, compared with a Healthcare industry average of about 22.73x and a peer group average around 92.58x. Simply Wall St also calculates a Fair Ratio for Chemed of 23.51x, which is intended to be a more tailored benchmark.

The Fair Ratio is a proprietary Simply Wall St metric that aims to estimate the P/E you might expect for a stock given factors such as its earnings growth profile, industry, profit margins, market cap and company specific risks. Because it pulls these inputs together into one number, it can give a more focused reference point than a simple comparison with industry or peer averages.

Chemed’s actual P/E of 21.44x sits below the Fair Ratio of 23.51x, which points to the stock looking UNDERVALUED on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Chemed Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you write a clear story for Chemed that connects your view on its hospice and Roto Rooter businesses to a forecast for revenue, earnings and margins, and then to a Fair Value that you can compare with the current price. The tool sits inside the Community page, updates automatically when fresh news or earnings arrive, and captures different viewpoints, such as one investor building a higher Fair Value around a US$580 target while another bases a more cautious view around US$400. This allows you to see exactly how different assumptions on the same stock lead to different conclusions about whether the current price looks attractive or not for your own decision making.

Do you think there's more to the story for Chemed? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com